Comparative expression analysis of embryonic development-related genes at different stages of parthenogenetic and in vitro fertilized embryos in caprine

Paternally and maternally imprinted gene perturbed expression in parthenogenetic diploid embryos in Capra hircus

The present research work was undertaken to compare the expression of paternally imprinted (P57KIP2, Grb10 and Xist) and maternally imprinted gene (Dlk1) among diploid parthenogenetic (DIP), female sexed in vivo and female sexed in vitro produced embryonic cell colony. The good quality caprine oocytes were matured in presence of cytochalasin B (CCB) and activated by ethanol (7%) for 5 min followed by incubation with 2 mM 6-dimethyl amino purine (DMAP) for 4 h for DIP embryos production. In vivo embryo was collected by surgical method from 10 super ovulated goats using Pluset®. In vitro embryos were produced by maturation of good quality oocyte followed by fertilization with superior male germplasm from the institute flock. Embryonic cell colony were developed from 8 to 16 and morula stage DIP, IVF and in vivo derived embryos. These colonies were used for studying the paternal and maternal imprinted genes expression. Karyotyping and sexing of embryonic cell colony was done to get only female sexed colony for this purpose. Paternally imprinted genes (P57KIP2, Grb10 and Xist) showed more expression in DIP compared to in vivo and IVF derived embryonic cell colony. The expression of maternally imprinted genes (Dlk1) was low in DIP compared to in vivo and IVF derived embryonic cell colony. The present study demonstrated that the expression profile of both paternal and maternally imprinted genes were perturbed, which may be responsible for developmental failure of parthenogenetic embryos to full term following parthenogenetic embryo transfer in goat.

Generation of Induced Pluripotent Stem Cells with Substitutes for Yamanaka's Four Transcription Factors

Induced pluripotent stem cells (iPSCs) share many characteristics with embryonic stem cells, but lack ethical controversy. They provide vast opportunities for disease modeling, pathogenesis understanding, therapeutic drug development, toxicology, organ synthesis, and treatment of degenerative disease. However, this procedure also has many potential challenges, including a slow generation time, low efficiency, partially reprogrammed colonies, as well as somatic coding mutations in the genome. Pioneered by Shinya Yamanaka's team in 2006, iPSCs were first generated by introducing four transcription factors: Oct 4, Sox 2, Klf 4, and c-Myc (OSKM). Of those factors, Klf 4 and c-Myc are oncogenes, which are potentially a tumor risk. Therefore, to avoid problems such as tumorigenesis and low throughput, one of the key strategies has been to use other methods, including members of the same subgroup of transcription factors, activators or inhibitors of signaling pathways, microRNAs, epigenetic modifiers, or even differentiation-associated factors, to functionally replace the reprogramming transcription factors. In this study, we will mainly focus on the advances in the generation of iPSCs with substitutes for OSKM. The identification and combination of novel proteins or chemicals, particularly small molecules, to induce pluripotency will provide useful tools to discover the molecular mechanisms governing reprogramming and ultimately lead to the development of new iPSC-based therapeutics for future clinical applications.